The UK Government will no longer seek to participate in the Unitary Patent or Unified Patent Court (UPC) system despite ratification of the agreement in 2018.

The UK IPO have issued new guidance on intellectual property during the Brexit transition period.

All European patent eyes were turned to Munich this week, and the much anticipated EPO Board of Appeal hearing in The Broad Institute's CRISPR case. In news that surprised no European Patent Attorneys at all (!), the appeal was dismissed, The Broad Institute's priority claim was held to be invalid, and the patent was revoked.

The European Patent Office predominantly uses the "problem-solution-approach" to assess whether an invention involves an inventive step. But what happens if the closest prior art document is not enabled, or if the results it describes are not reproducibly obtainable, because essential information is missing? And what if the secondary prior art document arguably discloses some of the information missing in the CPAD, but in a quite different context and without essential inform

This week, the UK Supreme Court handed down its much anticipated judgment in the Warner-Lambert v Mylan and Actavis (Lyrica) case. The...

Being able to prove chain of title for patent ownership is vital, but doesn't have to be complicated. Read Lucy's LinkedIn article that maps out the links in the chain for small entitles and multinationals, and contains advice on choice of assignment language and signatories (and even flags some tax pitfalls!).

Ask any patent practitioner the hardest territories in which to pursue pharmaceutical patents and they will probably mention Brazil. Idiosyncrasies in the way Brazil examines patent applications have caused huge delays in prosecution, as well as complaints of unfair rejections and even bias against foreign applicants.

The NY Times recently covered a fascinating deal between the pharmaceutical company Allergan and the Saint Regis Mohawk Tribe, a Native American tribe from New York.

Michael Caine from Davis Collison Cave Pty Ltd recently carried out a study to identify the various national requirements for the effective transfer of priority rights in accordance with Article 4A(1) of the Paris Convention. The study focused on the manner in which various countries and regions have implemented the provisions of Article 4A(1) and resulted in some useful guidelines.

The ruling of the UK Supreme Court in Actavis v Lilly (July 2017) has changed the way that patents will be interpreted in the UK, and, according to a new doctrine of equivalents, the scope of patent protection will exten